The use of immune checkpoint inhibitors (ICIs) has hugely incremented as it has become the standard therapy for a wide range of cancer types. Such monoclonal antibodies act against inhibitory immune receptors cytotoxic T-lymphocyte antigen 4 (CTLA-4) (ipilimumab and tremelimumab) and programmed cell death 1 (PD-1) (nivolumab and pembrolizumab) by boosting the immune response of T cells . Despite favourable oncological outcomes, these treatments have also been associated with a unique spectrum of side-effects known as immune-related adverse events (irAEs) .
Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast
Leggi l'articolo originale